HomeProductsBioactive CompoundsJAK/STAT SignalingJAKGandotinib
Chemical structure of CAS 1229236-86-5

Gandotinib

CAS No.1229236-86-5
MDL No.MFCD20482143
MFC23H25ClFN7O
MW469.90
InChI KeySQSZANZGUXWJEA-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Gandotinib is a pyridazine derivative.

CAS No.1229236-86-5
Product NameGandotinib

Biological Targets

JAK2

Associated Conditions

neoplasm
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020
PMID: 32020584PMC: PMC7160657DOI: 10.1111/imm.13175

Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.

Leukemia research • Vol. 71 • 2018
PMID: 30025280DOI: 10.1016/j.leukres.2018.06.014

Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors.

European journal of pharmacology • Vol. 765 • 2015
PMID: 26300391DOI: 10.1016/j.ejphar.2015.08.037

Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F.

Blood cancer journal • Vol. 3, Issue 4 • 2013
PMID: 23584399PMC: PMC3641321DOI: 10.1038/bcj.2013.6

Documentation